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Domperidone, a dopamine D2 receptor antagonist, is used as a prokinetic and anti-
emetic agent for the treatment of gastroparesis, nausea and vomiting (1). It is a poor water
soluble drug and is rapidly absorbed from the gastrointestinal (GI) tract. Its oral bioavail-
ability was reported in a range of 13–17 % (2). Poor aqueous solubility and extensive
first pass metabolism are the reasons for its low oral bioavailability. The approaches used
to improve oral bioavailability were: incorporation of the active lipophilic component
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The main objective of this work was to prepare a self-micro
emulsifying drug delivery system (SMEDDS) for enhan-
cement of oral bioavailability of domperidone, a poorly
water soluble drug. The solubility of the drug was deter-
mined in various vehicles. A pseudo ternary phase dia-
gram was constructed to identify the self-micro emulsifica-
tion region. The in vitro self-micro emulsification properties
and droplet size analysis of SMEDDS were studied fol-
lowing their addition to water under mild agitation. Furt-
her, the resultant formulations were investigated for clarity,
phase separation, globule size, effect of pH and dilutions
(1:100, 1:500, 1:1000) and freeze-thaw stability. The optimiz-
ed formulation, SMEDDS-B used for in vitro dissolution
and bioavailability assessment, contained oil (Labrafac CC,
25 %, m/m), surfactant (Tween 80, 55 %, m/m), and co-sur-
factant (Transcutol®, 20 %, m/m). The preliminary oral bio-
availability of domperidone from SMEDDS was 1.92-fold
higher compared to that of domperidone suspension in rats.
The AUC0-24 and cmax values were 3.38 ± 0.81 µg h mL–1 and
0.44 ± 0.03 µg mL–1 for SMEDDS-B formulation in com-
parison with 1.74 ± 0.18 µg h mL–1 and 0.24 ± 0.02 µg mL–1
for domperidone suspension, suggesting a significant in-
crease (p < 0.05) in oral bioavailability of domperidone
from SMEDDSS.
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into inert lipid vehicles such as oils, surfactant dispersions, liposomes, emulsions and
self-emulsifying formulations (3–5). Among these lipidic approaches, the self-emulsifying
drug delivery system (SEDDS) was used for lipophilic drugs with poor aqueous solubility
and low bioavailability after oral administration (6).
Self-emulsifying formulations comprise isotropic mixtures of natural or synthetic oils
with lipophilic or hydrophilic surfactants and co-solvent(s), which spontaneously emul-
sify when exposed to the GIT fluids to form oil-in-water emulsions or microemulsions
(6–10). Self-emulsifying formulations also provide the advantage of increased drug load-
ing capacity compared to lipid solutions, since the solubility of poorly water-soluble drugs
with intermediate partition coefficients (log P 2–4) is typically low in natural lipids and
much greater in amphiphilic surfactants, co-surfactants and co-solvents (11). Rapid emul-
sification of these systems under mild agitation and in the presence of aqueous media
such as GI fluids also generates a high surface area of interaction between the formu-
lation and the GI fluids and is thought to offer an improvement in the rate and extent of
absorption and result in more reproducible blood concentration time profiles.
The main aim of this study was to develop a domperidone SMEDDS by varying the
concentration of oils, surfactants, co-surfactant and optimization of the formulation by
ternary phase diagram. The SMEDDS were prepared and characterized for self-micro-
emulsification time, droplet size, and stability after dilution. Further, the optimized for-




Domperidone was a gift sample from Zydus Cadilla, India. Labrafac® CC, Labrafac
Lipophile WL-1349, Lauroglycol® 90, Labrasol® and Transcutol® were kindly supplied
by Gattefosse, USA. Captex-200, Capmul MCM were obtained from ABITEC Corpora-
tions, USA. Cremophore EL was obtained from BASF, India. Tween 80 was purchased
from Merck (India). All other chemicals and solvents used were of analytical grade.
Methods
Solubility studies. – The solubility of domperidone in different oils, surfactant and
cosurfactant combinations were determined. In brief, one mL of each vehicle was added
to each capped vial containing an excess of domperidone (0.05 g) (12, 13). The mixture
was heated for 2 min at 40 °C in a water bath and mixed using a vortex mixer. Then the
mixtures were shaken with a shaker at 25 °C for 24 h. After reaching equilibrium, each
vial was centrifuged at 4000 rpm for 10 min and excess insoluble domperidone was sepa-
rated by filtration using a membrane filter (0.45 µm, Whatman, USA). The solubility of
domperidone was determined by HPLC analysis (14).
The HPLC analysis system consisted of the mobile phase acetonitrile/doubly distilled
water/triethylamine (30:70:0.25, pH 2.5 adjusted with orthophosphoric acid) and 20-µL ali-
quot was injected into the HPLC column Lichrospher® 100, RP-18e (5 mm), 4.6 mm × 250 mm
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(Merck, Germany) in Shimadzu LC 20AD (Japan) solvent delivery pump and UV-Visible
Detector. The eluate was monitored at lmax 285 nm and the flow rate was 1 mL min–1.
HPLC. – Mobile phase was used to get standard solutions for calibration: 0.05, 0.1,
0.3, 0.5, 1.0, 5.0, and 10.0 µg mL–1. An aliquot of twenty µL of each solution was injected
onto HPLC column, peak area and retention time were noted and a standard graph was
plotted.
UV-Visible spectrophotometry. – Domperidone solutions of 100 µg mL–1 were prepared
in 0.1 mol L–1 HCl, pH 1.2, and phosphate buffer pH 6.8. From these solutions, dilutions
were made to obtain 5, 10, 15, 20, 25, 30, and 35 µg mL–1. Absorbance of domperidone
was measured with a UV–Visible Single Beam Spectrophotometer, Elico Ltd, India, at
lmax 283 nm.
Estimation of drug content in domperidone suspension. – About 40 mg of domperidone
was added to 5 mL of 2 % (m/V) sodium carboxymethyl cellulose mucilage and the final
volume was made up to 10 mL to produce 4 mg mL–1. From this, serial dilutions were
made. Drug content was estimated by HPLC.
Preparation of SMEDDS. – A series of self-micro emulsifying systems were prepared in
each of the four formulations with varying concentrations of Labrafac CC (20–35 % m/m),
Tween 80 (50–55 % m/m), and Transcutol (15–25 %, m/m) as oil, surfactant and co-sur-
factant. The SMEDDS were coded A, B, C and D (Table II). Domperidone was dissolved in
a glass test tube containing Transcutol at 60 °C in a water bath to facilitate solubilization.
Oil and surfactant were added and the final mixture was mixed by vortexing until a clear
solution was obtained (12, 13). The mixture was stored at room temperature until used.
Estimation of drug content in SMEDDS. – Initially 1.64 g of SMEDDS formulation con-
taining 40 mg of domperidone was diluted to 10 mL with doubly distilled water. From
this, serial dilutions were made. Drug content was estimated by HPLC.
Visual observations and construction of the phase diagram. – A series of formulations were
prepared with varying concentrations of oil (20–40 % m/m), surfactant (20–60 % m/m),
and co-surfactant (10–60 % m/m). Oil (Labrafac CC), surfactant (Tween 80 or Labrasol)
and co-surfactant (Transcutol) were added to the glass test tube and were mixed by vor-
texing until a clear solution was obtained (15, 16). The mixture was stored at room tem-
perature until used.
A visual test to assess that self-microemulsification was reported (4) and it was adopt-
ed in this study after modification (15). Formulation (50 µL) was introduced into 50 mL
of doubly distilled water in a glass beaker at 37 °C, and the contents were mixed gently
with a magnetic stir bar at 100 rpm. The tendency to microemulsify spontaneously and
microemulsion droplet formation as well as the final appearance of the microemulsion
were monitored. The tendency to form a microemulsion was rated »good« when drop-
lets were spread easily in water and formed a fine microemulsion that was clear or trans-
parent in appearance, while it was rated »bad« when the corresponding performance
was poor or there was less clear microemulsion formation, or emulsion formation. Phase
diagrams were constructed identifying the good self-microemulsifying region using the
Tri plot v1-4 software (Fig. 1) (13).
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In vitro drug release studies. – Drug release was studied by the dialysis bag method.
Initially, the dialysis tubing was soaked in the specified medium for 1 h at 40 °C (12).
The quantitative in vitro release test was performed in simulated gastric fluid (0.1 mol L–1
HCl, pH 1.2) and also in simulated intestinal fluid (pH 6.8). SMEDDS formulation (410 mg)
containing 10 mg of domperidone was placed in the dialysis bag made up of the mem-
brane having the molecular mass cut off 12,000–14,000 (Himedia, India) and then sus-
pended in a 250-mL beaker containing 200 mL of the medium. The contents were mixed
gently with a magnetic stir bar at 100 rpm and release patterns were studied at room
temperature. At different time intervals up to 24 h, 1-mL samples of the medium were
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Fig. 1. Ternary phase diagram of series I consisting of Labrafac CC, Tween 80 and Transcutol and of
series II consisting of Labrafac CC, Labrasol and Transcutol (dark shaded area indicates the SMEDDS
formation and the light shaded area does not indicate SMEDDS formation.
Table I. Solubility of domperidone in different oils, surfactants and cosurfactant
Vehicle Solubility (mg mL–1)
Captex-200P 2.64 ± 2.19
Lauroglycol 90 5.84 ± 3.13
Labrafac CC 31.49 ± 2.72
Labrafac Lipophile WL-1349 0.92 ± 0.88
Cremophore EL 2.29 ± 2.06
Labrasol 14.22 ± 4.42
Tween 80 12.16 ± 5.18
Capmul MCM 1.39 ± 1.22
Transcutol 288.08 ± 43.58
Mean ± SD, n = 3.
collected and replaced with equal volumes of fresh medium. No enzymes were added to
the medium. All the samples were analyzed at lmax 283 nm after appropriate dilution.
Assessment of self-microemulsification time. – Evaluation of the self-microemulsifying
properties of SMEDDS formulations was performed by visual assessment (13). The time
taken for the microemulsion formation (until a transparent system was obtained) was
noticed upon dropwise addition of 100 µL of SMEDDS into 100 mL of distilled water in
a glass beaker at 37 °C, and the contents were stirred magnetically at 100 rpm (17).
Phase separation and stability study of microemulsion. – Each SMEDDS (50 µL) was added
to a glass test tube containing 5 mL doubly distilled water at 37 °C (16). After 1 minute
of vortex mixing, each mixture was stored for a period of 2 h and observed for phase
separation and precipitation of the drug, if any. Further, observations were also made
after 4, 6, 8, 12 and 24 h.
Droplet size analysis. – Formulation (50 mL) was introduced into 50 mL of doubly dis-
tilled water in a glass beaker at 37 °C, and the contents were mixed gently with a magne-
tic stir bar at 100 rpm (13, 15). The resultant microemulsion was then subjected to droplet
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Table II. Formulation composition, droplet size and polydispersity index (PDI) and self-micro













SMEDDS-A 20 55 25 46.28 ± 7.24 0.25 ± 0.18 20.96 ± 2.63
SMEDDS-B 25 55 20 25.47 ± 3.06 0.26 ± 0.06 25.55 ± 2.02
SMEDDS-C 30 50 20 74.74 ± 12.07 0.35 ± 0.13 30.46 ± 2.08
SMEDDS-D 35 50 15 87.86 ± 7.40 0.42 ± 0.15 32.27 ± 2.41
SMEDDS A, B, C and D belong to series I. PDI – polydispersity index
Table III. Effect of dilution with distilled water and pH media on the SMEDDS droplet size
Treatment
Droplet size (nm)
SMEDDS-A SMEDDS-B SMEDDS-C SMEDDS-D
Water 1:10 39.70 ± 8.61 20.18 ± 7.45 112.10 ± 8.60 135.57 ± 6.88
1:100 46.60 ± 11.05 22.91 ± 5.28 86.64 ± 7.53 104.99 ± 10.62
1:500 42.15 ± 4.80 27.99 ± 3.07 73.49 ± 9.44 93.42 ± 5.80
1:1000 46.28 ± 7.24 25.47 ± 3.06 74.74 ± 12.07 87.86 ± 7.40
HCl, 0.1 mol L–1, pH 1.2 49.17 ± 4.44 25.68 ± 4.28 73.41 ± 6.86 91.73 ± 6.59
Phosphate buffer, pH 6.8 49.10 ± 3.98 28.21 ± 3.92 82.18 ± 3.83 92.12 ± 3.30
Mean ± SD, n = 3.
size analysis. The size of the globule was measured at the 90° angle and at the tempera-
ture of 25 °C by a Malvern Zetasizer (Nano ZS90, Malvern, UK). The average of three
readings was noted.
Effect of dilution and pH on droplet size. – To evaluate the effect of dilution on the drop-
let size of the resultant microemulsion, SMEDDS formulations were subjected to dilutions
(1:10, 1:100, 1:500, and 1:1000) and size of globules was measured.
To evaluate the effect of pH, SMEDDS formulations were diluted (1:1000 dilution)
with doubly distilled water, 0.1 mol L–1 HCl (pH 1.2) and pH 6.8 phosphate buffer.
Then, the resultant microemulsions were subjected to droplet size analysis.
Physical stability of the SMEDDS during freeze and thawing and storage. – The formula-
tions in Eppendorf tubes were subjected to 4 to 5 freeze-thaw cycles, which included
freezing at –20 °C for 24 h followed by thawing at 40 °C for 24 h (13). After completion
of 5 freeze-thaw cycles, the formulations were centrifuged at 3000 rpm for 5 min. The
formulations were then observed for phase separation, and precipitation of the drug, if
any. After completion of freeze thaw study, the same SMEDDS formulations were stored
at room temperature for 6 months and observed for phase separation, and precipitation
of the drug.
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Fig. 2. a) Cumulative percent drug release from SMEDDS formulations at: a) pH 1.2, b) pH 6.8;




Animals. – Healthy male Wistar rats (270–350 g) were used for the pharmacokinetic
study. The animals were given a diet recommended by the National Institute of Nutri-
tion, Hyderabad, India, and had free access to water. The studies were conducted with
prior approval of institutional ethical committee, University College of Pharmaceutical
Sciences, Kakatiya University, Warangal, India.
Study protocol. – The animals were divided into two groups (6 animals each) and
were randomly administered each treatment. The following treatments were given at a
single dose of 10 mg kg–1 body mass orally. The SMEDDS B formulation and suspension
were administered after about 8 to 10 h of fasting to each group of animals. At appropri-
ate predetermined time intervals after oral administration, blood samples were collected
by puncturing the retro-orbital venous plexus. The blood was allowed to clot, centri-
fuged at 5000×g for 10 min and serum was collected. Serum samples were stored at –20
°C until analysis. Serum samples were extracted with dichloromethane and serum
domperidone levels were estimated by HPLC. Drug content in serum samples was esti-
mated by following the procedure that follows. To 100 µL of blank serum, 100 µL of
domperidone standard solution in mobile phase was added, containing 0.2, 0.3, 0.5, 1.0
or 5.0 µg mL–1 of domperidone (14). One hundred fifty nanograms of propranolol in metha-
nol (100 µL) as internal standard, 100 µL of 0.1 mol L–1 NaOH, and 3 mL of dichloro-
methane were added. The mixture was shaken for 10 min and centrifuged at 3000×g for
10 min, then the organic phase was transferred to another glass tube and evaporated to
dryness using a vacuum evaporator. The dried residue was dissolved in 100 µL of mo-
bile phase [acetonitrile/25 mmol L–1 phosphate buffer/trietylamine (35:65:0.25)] pH 2.5
was adjusted with orthophosphoric acid and twenty µL of aliquot was injected into the
HPLC column. Peak area and retention time were noted for all samples and the standard
graph was plotted. Pharmacokinetic parameters (PK) cmax, tmax, AUC, t1/2 and mean res-
idence time (MRT) were calculated using Kinetica software (18).
Statistical significance of observed differences in pharmacokinetic parameters of different
groups was assessed by ANOVA. The pharmacokinetic data was expressed as mean ± SD,
and two sample comparisons were performed using the unpaired t-test. p < 0.05 was
considered to indicate statistically significant difference.
RESULTS AND DISCUSSION
Preparation of SMEDDS
Labrafac CC (oil), Labrasol and Tween 80 (surfactants) and Transcutol (co-surfactant)
showed higher solubility for domperidone (Table I) when compared with the others agents
tested. The self-micro emulsification region was mainly dependant on the concentration of
Transcutol and Tween 80. SMEDDS were formed when the concentration of Tween 80 was
50–60 % (m/m), provided that the concentration of Transcutol was less or equal to 25 %
(m/m), above which SMEDDS were not formed. From the phase diagrams (Fig. 1), it was
observed that series I (consisting of Labrafac CC, Tween 80 and Transcutol) had a large self-
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-micro emulsifying domain and series II (consisting of Labrafac CC, Labrasol and Trans-
cutol) had no such domain. So series I, consisting of Labrafac CC (20–40 %, m/m), Tween
80 (50–60 %, m/m) and Transcutol (10–25 %, m/m) was selected for the further study.
It was observed that increasing the concentration of the co-surfactant, Transcutol,
within the SMEDDS forming region increased the spontaneity of the self-microemulsifi-
cation process. When a co-surfactant was added to the system, it further lowered the in-
terfacial tension between the O/W interfaces and also influenced the interfacial film cur-
vature, which thereby readily formed the micro-emulsions upon dilution.
In SMEDDS, increasing the surfactant Tween 80 concentration decreased the mean
droplet size (Table II). The effect of co-surfactant concentration on the droplet size distri-
bution in SMEDDS was similar to that of the surfactant Tween 80 when concentrations of
transcutol changed from 10 to 25 % m/m. When a co-surfactant was added (in addition to
surfactant) to the system, it lowered the interfacial tension, fluidized the hydrocarbon re-
gion of the interfacial film, and decreased the bending stress of the interface (19).
In vitro drug release and stability
The in vitro drug release studies were performed for SMEDDS A, B, C and D formu-
lations. The cumulative percentage release (Figs. 2a and 2b) of domperidone from the
SMEDDS-B formulation was significantly higher than that of other formulations, which
might be due to the small droplet size.
In general, during the dilution studies with water no significant difference was found
in the droplet size of A and B formulations, whereas, in case of formulations C and D it
resulted in decreased droplet size (Table III). The different media pHs could not alter the
droplet sizes significantly in any SMEDDS formulation (Table III). SMEDDS A and B re-
sulted droplet size less than 50 nm. Diluted upto 1000 times either with water or media.
Whereas in case of SMEDDS-C and -D the size was significantly higher. This difference
in size was probably due to the relatively smaller oil portion and more surfactant and
co-surfactant in case of SMEDDS A and B. SMEDDS-B showed almost 50 % lower size
compared to SMEDDS-A. Thus, SMEDDS-B was found to be superior to the others.
The freeze-thaw studies of the SMEDDS formulation did not show any changes in
the stability, i.e., phase separation and precipitation of the drug even after storage for six
months at room temperature. Stability of the resulting microemulsion after 1:100 dilution
with distilled water was studied up to 24 h. During this period no phase separation and
precipitation were noticed.
Bioavailability
Based on the self-emulsification properties, particle size, drug release data and stabil-
ity of micro emulsion, formulation-B was selected for bioavailability studies. The plasma
profiles of domperidone in rats following oral administration of the suspension and
SMEDDS-B formulation were compared. The plasma concentration profiles of domperidone
SMEDDS-B formulation showed higher drug levels at all time points than that of the sus-
pension. As shown in Table IV, the AUC0–24 and cmax values were 3.37 ± 0.81 µg h mL–1 and
0.44 ± 0.03 µg mL–1 for SMEDDS-B formulation in comparison with 1.74 ± 0.18 µg h mL–1
and 0.24 ± 0.02 µg mL–1 for domperidone suspension, suggesting a significant increase
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(p < 0.05) in oral bioavailability of the SMEDDS formulation. However, the tmax, t1/2 and
MRT values (in h) were: 0.58 ± 0.20, 6.68 ± 1.57, 8.9 ± 1.72 and 0.50 ± 0.00, 6.65 ± 0.61,
8.04 ± 0.85 for the SMEDDS-B and domperidone suspension respectively. The relative bio-
availability of the SMEDDS-B formulation was 1.9-fold higher compared to the suspen-
sion. The reason for enhanced oral bioavailability of SMEDDS-B might be due to its lym-
phatic transport. It has been also reported that the long-chain oils promote lipoprotein
synthesis and subsequent lymphatic absorption (20). The spontaneously formed emul-
sion, upon drug release in the GI tract, effectively presents the drug in a solubilised state,
and the small droplet size would provide a large interfacial surface area for drug absorp-
tion (3). The main rate-limiting barrier for drug absorption/diffusion is the single layer of
intestinal epithelial cells. High content of surfactants in SMEDDS could enhance the per-
meability by disturbing the cell membrane (21). The surfactant with the best enhancement
ability requires both hydrophilic and lipophilic domains, such as Tween 80. Its structural
characteristics impart both lipophilic and hydrophilic properties to the surfactant, allow-
ing it to partition between lipid and protein domains. The surfactant was demonstrated
to have a reversible effect on the opening of a tight junction and it might interact with
the polar head groups of lipid bilayers, modifying hydrogen bonding and ionic forces
between these groups. It may also insert itself between the lipophilic tails of the bilayers,
resulting in disruption of the lipid-packing arrangement (22). Therefore, drug delivery
using SMEDDS is a promising approach for the effective absorption and rapid onset of
action after oral administration of this drug and for improvement of its oral bioavail-
ability.
CONCLUSIONS
Domperidone, being a lipophilic drug, was formulated as SMEDDS based on the oil
solubility studies and ternary phase diagrams. Optimal formulation, SMEDDS-B, was
developed based on in vitro experiments, used in oral bioavailabilty studies in rats and
compared with a suspension. The preliminary oral bioavailability study of SMEDDS-B
showed improvement by a factor of 1.9 compared to the suspension in rats. Thus SMEDDS
may be used for improvement of oral bioavailabilty of drugs with poor water solubility
and low oral bioavailability.
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Table IV. The pharmacokinetic parameters of domperidone in rats
Parameter SMEDDS-B Domperidone suspension
cmax (µg mL–1) 0.44 ± 0.04a 0.24 ± 0.02
tmax (h) 0.58 ± 0.20 0.50 ± 0.00
AUCtotal(µg h mL–1) 3.37 ± 0.81a 1.74 ± 0.18
t1/2 (h) 6.68 ± 1.57 6.65 ± 0.61
MRT (h) 8.90 ± 1.72 8.04 ± 0.85
Mean ± SD, n = 6.
a Domperidone SMEDDS-B formulation significantly different from the suspension at p<0.05 (unpaired t-test).
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